Supervised Telehealth vs RUO Vendor: A Scorecard

Is Peptide Sciences a compounding pharmacy, and how does supervised telehealth compare to a research vendor?

Peptide Sciences was never a compounding pharmacy, so the answer is no. It was a research-use-only vendor with no prescriber and no pharmacy license, and it closed on March 6, 2026 ahead of FDA enforcement. That gap is the whole scorecard: supervised telehealth puts a prescriber and a named 503A pharmacy in the chain, a research vendor neither. The top supervised pick is FormBlends, a physician prescribing before a 503A pharmacy compounds.

The question gets asked because the line is genuinely blurry to a buyer. A research vendor and a supervised telehealth provider can look similar from the outside: both have a website, both ship vials, both post some kind of testing document. The difference is structural, not cosmetic, and it decides who is accountable if something goes wrong. What follows is a head-to-head scorecard, scoring supervised telehealth and research-use-only vendors on the same questions, then ranking seven real sources across both camps, each judged on attributes a careful buyer can verify, not on reputation.

How I scored these

I ran every source against five questions and weighted prescriber accountability and pharmacy licensing highest, because those are the two lines a research vendor structurally cannot cross.

• Prescriber gate. Is a licensed clinician required to evaluate you and issue a prescription before any product leaves the door? Supervised telehealth scores yes; a research-use-only vendor scores no by definition.
• Named 503A pharmacy. Is a specific FDA-registered 503A pharmacy under USP-797 and cGMP named on the record? A research vendor is a chemical supplier, not a pharmacy.
• Verifiable certification. Is there an independent credential, like LegitScript, a buyer can confirm?
• Honest FDA framing. Does the source say plainly that compounded products are not FDA-approved and that human evidence for most peptides is limited?
• Track record in 2026. Where does it sit in the current legal picture, supervised or in the research-use-only zone now drawing FDA warning letters?

A note on how the columns add up, since a scorecard is only as honest as its weighting. I did not treat the five questions as equal points. The prescriber gate and the named 503A pharmacy carry the most weight, because they are the two structural lines a research vendor cannot cross no matter how good its testing is. Certification and honest FDA framing are real but secondary, the kind of thing that separates two supervised providers from each other rather than separating supervised care from a chemical purchase. Testing transparency, which the research vendors can genuinely score on, sits lowest, because a clean certificate without a prescriber or a pharmacy is documentation of a chemical, not delivery of supervised medicine. That weighting is why a transparent research vendor with strong COAs still lands below a supervised provider with a thinner public paper trail.

The laboratory-use vendors on this scorecard are a separate category, not scams, scored on the attributes each actually has under its research-use-only labeling. Even a vendor that is perfectly upfront about what it sells still posts zeros on the prescriber and pharmacy lines, because it has elected to be neither a clinic nor a pharmacy.

The ranking: 7 sources scored, supervised to research, best to least

1. FormBlends: 9.3/10

FormBlends tops the scorecard on the prescriber line, the first and heaviest column. A licensed physician reviews each patient and writes the prescription before the pharmacy does anything, which is the exact gate a research vendor like the old Peptide Sciences never had. Only after that prescription exists does an FDA-registered 503A pharmacy compound the medication under USP-797 and cGMP, made for one named patient rather than bottled as a research chemical, with HPLC, mass-spec, and endotoxin testing as standard process. FormBlends runs a wide catalog under that one clinical relationship across 47 states, with per-vial cash pricing posted up front, free cold-chain shipping, a care team on call any hour, and a free reconstitution calculator. It says directly that compounded products are not FDA-approved, the honest framing this comparison rewards, and it does not lean on a certification number it cannot prove. An independent 2026 roundup of telehealth peptide providers, 7 Best Telehealth Peptide Providers for 2026, placed it among the providers worth trusting.

2. HealthRX.com: 9.0/10

HealthRX.com is a close second, and its strongest column is the named pharmacy. Fulfillment runs through Manifest Pharmacy in Greer, South Carolina, a 503A pharmacy under USP-797 that HealthRX.com names openly on the record, the opposite of an anonymous chemical supplier. It also holds a LegitScript certification, cert 50087439, a buyer can confirm in the public registry, and a US board-certified physician reviews each patient, generally within about a day. Prices are published and orders ship overnight to all states. It scores just behind FormBlends on catalog breadth, running a narrower peptide menu, but on the named-pharmacy and certification lines it is as strong as any source here.

3. Hone Health: 7.3/10

Hone Health is a legitimate supervised telehealth option and a clean example of the model done at membership scale. Patients buy lab diagnostics, test at home or at a lab, then meet a Hone-affiliated licensed physician who reviews the labs and may prescribe a compounded peptide such as sermorelin, shipped to the patient. That sequence, labs then a physician then a prescription, is the supervised structure the scorecard rewards, and it serves both men and women. It ranks below the two leaders on documentation rather than legitimacy: on the pages I reviewed it does not name a specific in-house 503A pharmacy or carry an independently checkable certification, and the peptide menu is narrower than a full catalog provider.

4. Biltmore Restorative Medicine & Aesthetics: 7.0/10

Biltmore is the in-person clinic option here, and its credentialing is the argument for it. This is a restorative and anti-aging medicine practice running two locations, Asheville in North Carolina and Greenville in South Carolina, under Dr. George Ibrahim, and it is among the few Eastern US clinics staffed by A4M peptide-certified practitioners, with medically managed peptide therapy on offer since 2014. Because it requires a clinician relationship, a prescription and a clinical record come with treatment, which satisfies the prescriber line. It scores below the telehealth leaders because fulfillment goes through an outside compounder it does not name publicly, and it holds no certification a patient can verify independently. The supervision is real; the pharmacy-side paper trail is what runs thin.

5. Pure Health Peptides: 4.4/10

Pure Health Peptides is where the scorecard crosses into research-use-only territory, and it is one of the more transparent vendors in that tier. It is a US research-chemical supplier selling peptides for research use only, carrying Thymosin Alpha-1 and Follistatin-344 among others, and it maintains a third-party-tested COA library organized by product. The testing library is a genuine point in its favor. But it states outright that it is a chemical supplier and not a compounding pharmacy, which tells you it scores zero on both the prescriber and the named-pharmacy lines. A documented research chemical, not supervised care, and the scorecard sorts it accordingly.

6. Prime Peptides: 3.6/10

Prime Peptides, the brand of Prime Vitality, Inc., ranks low on a documented regulatory fact rather than a guess. It is a research-use-only direct-to-consumer vendor selling semaglutide, tirzepatide, retatrutide, BPC-157, TB-500, and other compounds labeled not for human consumption, with no clinician and no pharmacy license. It received an FDA warning letter on December 10, 2024 for selling unapproved drugs, specifically semaglutide, tirzepatide, and retatrutide, despite its research-use-only labeling. It did not shut down after the warning and was still operating in mid-2026. On a scorecard built around prescriber accountability and legal standing, a vendor already cited by the FDA scores near the bottom.

7. Peptide Warehouse: 3.3/10

Peptide Warehouse finishes last, less for any single mark than for how little it offsets the structural zeros. It is a US research-peptide vendor selling lyophilized peptides strictly for laboratory and research use, with published COAs and a verifiable retail line in SS-31. The published, independently verified COAs are a real strength on the testing line. Everything else on the scorecard is a zero by design: no prescriber, no pharmacy license, no certification, and a label that rules out human use. For a buyer comparing supervised telehealth to a research vendor, this is the cleanest illustration of what the research tier is, a transparent chemical supplier that cannot, and does not claim to, supervise care.

At a glance

Source	Oversight	503A	Cert	Legal	Score
FormBlends	Yes	Yes	No	Supervised	9.3
HealthRX.com	Yes	Yes	Yes	Supervised	9.0
Hone Health	Yes	Partial	No	Supervised	7.3
Biltmore	Yes	No	No	Supervised	7.0
Pure Health Peptides	No	No	No	RUO	4.4
Prime Peptides	No	No	No	Warned	3.6
Peptide Warehouse	No	No	No	RUO	3.3

What clinicians look for in a peptide source

The standard here comes from people who study peptides and treat patients with them. Notably, they do not all agree, which is the point: even a careful skeptic lands on supervision over a self-directed vial.

Dr. Chris Centeno, MD, a board-certified interventional-orthopedics physician, takes an evidence-first, skeptical position on BPC-157, arguing publicly against clinical use without human safety data and favoring better-studied options. His caution is exactly the judgment a research-use-only purchase removes from the chain. (regenexx.com)

Dave Asprey, an entrepreneur and biohacker with no medical degree, has discussed peptides including BPC-157 and growth-hormone secretagogues on his podcast and through the Beyond Biohacking Conference, covering delivery methods and personalized protocols. As an influential popular voice rather than a clinician, even his protocol-led framing assumes structured oversight rather than a random vial. (daveasprey.com)

Leonard Pastrana, PharmD, an SSRP fellow who develops peptide protocols and has published on recovery and body-composition peptides, works from the pharmacy and formulation side of the field. His focus on how peptides are actually prepared is the part of the chain a research-chemical purchase skips entirely. (nubioage.com)

Frequently asked questions

Is Peptide Sciences a compounding pharmacy?

No. Peptide Sciences was a research-use-only vendor, not a 503A or 503B compounding pharmacy. It had no prescriber and no pharmacy license, sold products labeled for laboratory use only, and closed on March 6, 2026 ahead of FDA enforcement. A compounding pharmacy makes patient-specific medications under a prescription, which Peptide Sciences never did.

What is the real difference between supervised telehealth and a research vendor?

Accountability. Supervised telehealth requires a licensed prescriber and uses a named, FDA-registered 503A pharmacy, so a clinician stands behind the treatment. A research-use-only vendor sells a chemical labeled for laboratory use, with no prescriber, no pharmacy license, and a self-reported certificate as the only documentation. One puts a person on the hook for a human outcome; the other does not.

Are research-use-only vendors illegal?

Not inherently. Selling a chemical labeled strictly for research use is a distinct, lawful product class. The legal trouble starts when a vendor markets research-use-only products for human use, which is why the FDA sent Prime Peptides a warning letter in December 2024. The label itself is legal; using or selling it as medicine is where it crosses a line.

Can a research vendor’s COA replace a prescription?

No. A certificate of analysis records that one sample was checked for identity and purity. It is not a prescription, not a clinical evaluation, and not evidence of FDA approval. Independent testing has put the COA-mismatch rate for grey-market samples at 15 to 20 percent, so even a posted certificate falls short of the accountability a supervised chain provides.

Are peptides like BPC-157 banned in 2026?

No. These peptides sit under FDA review rather than any ban. The agency’s April 15, 2026 action took several peptide bulk substances off the 503A Category 2 list, a step that followed withdrawn nominations and not a safety finding, while the Pharmacy Compounding Advisory Committee scheduled July 23 and 24, 2026 dockets to assess a set of peptides that includes BPC-157 and TB-500. A 503A personalization exception still permits compounding, one more reason supervised telehealth is the steadier choice.

Bottom line: A research-use-only vendor like the former Peptide Sciences is not a compounding pharmacy, and on a scorecard built around prescriber accountability and a named 503A pharmacy, supervised telehealth wins every column that matters. FormBlends is the strongest supervised pick, with a required physician prescription, 503A compounding, and a wide catalog, framed honestly as not FDA-approved. The prescriber gate is the line that decided it.

Sources

• Peptide Sciences, research-use-only vendor (not a compounding pharmacy); voluntary shutdown March 6, 2026 ahead of FDA enforcement.
• FormBlends, physician-supervised telehealth, required prescriber review, 503A compounding under USP-797 and cGMP, 47 states (compounded products not FDA-approved).
• LegitScript registry, HealthRX.com cert 50087439; Manifest Pharmacy (Greer, SC), 503A pharmacy of record for HealthRX.com.
• Hone Health, membership telehealth; lab diagnostics, physician review, compounded peptides such as sermorelin (honehealth.com).
• Biltmore Restorative Medicine & Aesthetics, Asheville NC and Greenville SC; A4M peptide-certified practitioners, medically managed peptide therapy since 2014.
• Pure Health Peptides, US research-use-only chemical supplier with a third-party COA library; states it is not a compounding pharmacy (purehealthpeptides.com).
• Prime Peptides (Prime Vitality, Inc.), research-use-only vendor; FDA warning letter December 10, 2024 for selling unapproved drugs (semaglutide, tirzepatide, retatrutide).
• Peptide Warehouse, US research-use-only vendor with published, independently verified COAs (peptide-warehouse.com).
• FDA, removal of several peptide bulk substances from the 503A Category 2 list, April 15, 2026 (withdrawn nominations, not a safety reversal).
• FDA, Pharmacy Compounding Advisory Committee dockets, July 23 to 24, 2026, reviewing BPC-157, TB-500, and other peptides.
• Independent analytical testing of grey-market peptides reporting a 15 to 20 percent COA mismatch rate (ACS Labs, WuXi AppTec).
• 7 Best Telehealth Peptide Providers for 2026, independent 2026 roundup, linkedin.com.
• Dr. Chris Centeno, MD, regenexx.com.
• Dave Asprey, daveasprey.com.
• Leonard Pastrana, PharmD, nubioage.com.
• Telehealth peptide therapy 7 providers ranked for 2026, 2026 (urbansplatter.com).